Although in both genders, targeted treatments appeared to reduce the volume of drinking, treatment with targeted naltrexone was somewhat better. In contrast, heavy drinking women showed no benefit from daily naltrexone treatment. Further evaluation of the efficacy of targeted treatments and of daily naltrexone and the relationship of these treatments with gender is warranted.
Technical variant techniques expand the pediatric donor pool and reduce time from listing to transplant, but they are associated with increased morbidity and mortality.
BackgroundMany different test statistics have been proposed to test for spatial clustering. Some of these statistics have been widely used in various applications. In this paper, we use an existing collection of 1,220,000 simulated benchmark data, generated under 51 different clustering models, to compare the statistical power of several disease clustering tests. These tests are Besag-Newell's R, Cuzick-Edwards' k-Nearest Neighbors (k-NN), the spatial scan statistic, Tango's Maximized Excess Events Test (MEET), Swartz' entropy test, Whittemore's test, Moran's I and a modification of Moran's I.ResultsExcept for Moran's I and Whittemore's test, all other tests have good power for detecting some kind of clustering. The spatial scan statistic is good at detecting localized clusters. Tango's MEET is good at detecting global clustering. With appropriate choice of parameter, Besag-Newell's R and Cuzick-Edwards' k-NN also perform well.ConclusionThe power varies greatly for different test statistics and alternative clustering models. Consideration of the power is important before we decide which test statistic to use.
The outcomes of 113 children with autoimmune hepatitis (AIH), registered with Studies of Pediatric Liver Transplantation and who underwent transplantation between 1995 and 2006, were compared with those who underwent transplantation for other diagnoses (non-AIH). A total of 4.9% of liver transplants were for AIH; 81% of these patients had AIH type 1 and most underwent transplantation for complications of chronic disease (60%), the majority in females (72%). Transplantation for fulminant AIH was more common in males (52.5% versus 47.5% chronic; P ¼ 0.042). Patients with AIH differed from non-AIH patients by: age (13.0 6 0.4 versus 4.6 6 0.1 years; P < 0.0001), sex (64.6% female versus 52.9%; P ¼ 0.016), ethnicity (48.7% white versus 58.2%; P < 0.0001), initial immunosuppression (tacrolimus-based: 72.6% versus 62.6%; P ¼ 0.045; mycophenolate mofetil use: 31.0% versus 21.6%; P ¼ 0.02), and immunosuppression at 2 years after transplant (monotherapy: 51.9% versus 17.3%; P < 0.0001). Late (>3 months), but not steroid-resistant or chronic, rejection was more common in AIH (log-rank P ¼ 0.0015). The 5-year posttransplant survival for AIH was 86% (95% confidence interval: 73-93). Patient and graft survival, infectious and metabolic complications, and retransplantation rates did not differ between AIH and non-AIH groups. In conclusion, the higher risk for late acute rejection and greater degree of immunosuppression does not compromise outcomes of liver transplantation for AIH. Children who undergo transplantation for AIH in North America are typically female adolescents with complications of chronic AIH type 1 and include more children of African American or Latino American origin compared to the overall liver transplant population. These observations may inform detection, treatment, and surveillance strategies designed to reduce the progression of autoimmune hepatitis and subsequently, the need for transplantation.
When publishing cancer maps we recommend evaluating the spatial patterns observed using Tango's MEET, a global clustering test, and the spatial scan statistic, a cluster detection test.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.